Moneycontrol PRO
LAMF
LAMF

Schizophrenia

Jump to
  • Schizophrenia symptoms, causes, and treatment: What you need to know

    Schizophrenia is a psychiatric disorder affecting thought, perception, and behaviour. Key features include hallucinations, delusions, thought broadcasting, neologisms, echolalia, verbigeration, and thought blocking. It affects all demographics. Diagnosis involves imaging, and treatment includes psychosocial rehabilitation and pharmacological therapy

  • Study finds links between mental health conditions and career choices among individuals

    The research, published in Nature Human Behaviour, examined 20 professional fields and identified clear patterns. Artists and designers were found to have the strongest predisposition to a range of mental health conditions, including bipolar disorder, schizophrenia, autism, depression, and anorexia.

  • World Mental Health Day 2024: 7 compelling films to watch and where to watch them

    World Mental Health Day is observed globally on October 10 every year. Here is a list of films that you can watch on the day that explore myriad forms of mental health disorders through a humane lens.

  • World Schizophrenia Awareness Day 2024: How can patients live a normal life with other people

    World Schizophrenia Awareness Day 2024: People with schizophrenia present most common symptoms such as hallucinations (Seeing, hearing, smelling, or feeling things that are not real), delusions, disorganised thoughts, unusual body movements and cognitive disorders.

  • World Schizophrenia Day 2024: Common myths and facts about this mental disorder

    World Schizophrenia Day 2024: A lack of motivation, disordered thinking, and social disengagement are signs of this disorder. Here are few misconceptions related to schizophrenia. By busting these widespread misconceptions, we can advance a more realistic and caring viewpoint, promoting improved mental health services and lowering stigma.

  • Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion

    Under the terms of the deal, Bristol would pay $330 a share in cash for Karuna, which represents a 53.4% premium to its last closing price.

  • Deciphering schizophrenia: It's not easy to understand patient's delusions, but be patient with them

    Schizophrenia often leads to delusions and hallucinations. You can support a patient deal with this challenging mental illness by validating their fears, encouraging them to express themselves and staying connected, and by recognising signs of danger.

  • World Mental Health Day 2023: The global burden of mental health disorders

    On World Mental Health Day, October 10, know the data: pre-pandemic, in 2019, an estimated 970 million people in the world were living with a mental disorder; worldwide, 1 in 8 individual lives with a mental health condition, countries spend only 2 per cent of health budgets on treatment and prevention of mental health conditions.

  • China probes case of chained woman in shack after outcry

  • Indian govt's schizophrenia led to COVID ravages: Amartya Sen

  • Scientists identify brain activity pattern that may predict schizophrenia

  • Suven Life Sciences gets 1 product patent in India; shares up 3%

  • Suven Life Sciences shares up 5% on patents from Europe, Israel

  • Suven Life shares up 5% on patents in Canada, Europe & Hong Kong

  • Suven Life gets patents for neurodegenerative drug

  • Suven Life gets patents for neurodegenerative drug

  • Suven Life Sciences gets patents for neurodegenerative drug

  • Suven Life Sciences gets patents for neurological drug

  • Suven gets patents for neuro-degenerative disorder drug

  • Suven Life up 4%, begins clinical trials of alzheimer drug

  • Suven Life gets patents for molecules in three countries

  • Suven Life up 9% on product patents in Canada, Japan, Korea

  • Suven Life Sciences gets patent for neuro-degenerative drug

  • Suven at record high on Alzheimer drug's US clinical trial

  • Sun Pharma up 3%, arm gets USFDA nod for schizophrenia drug

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347